NCT04590274

Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: International Brain Research Foundation · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family. The coronaviruses are largely responsible for the common cold, the 2002 SARS outbreak in Guangdong, China, the 2012 MERS outbreak in Saudi Arabia, and the present COVID-19 outbreak that originated in Wuhan, China. Much has been reported by way of systemic injury caused by COVID-19 affecting the cardiovascular, hepatic, nervous systems. These conditions are likely the result of the virus overwhelming the immune system. For these reasons, the investigators wish to conduct this study using existing medications off-label, and over-the-counter supplements to support the immune response, prevent lasting injury, and hasten the recovery from COVID-19.

Conditions

• Covid19
• SARS (Severe Acute Respiratory Syndrome)

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Hydroxychloroquine
DIETARY_SUPPLEMENT	Vitamins and Minerals	elemental Zinc Vitamin C Vitamin D3 N-acetylcysteine Elderberry Quercetin
DRUG	Azithromycin	Azithromycin

Timeline

• Start date: 2020-11-01
• Primary completion: 2021-12-01
• Completion: 2021-12-01
• First posted: 2020-10-19
• Last updated: 2021-12-07

Regulatory

• FDA-regulated drug study